The AGM statement contains no new news and indicates trading remains on track. The shares have given back some of their strong gains in recent weeks to a level we think looks relatively good value. The next potential catalyst will be news on the lifting of the Article 31 restriction on Cardioxane, which is expected in the next 6 months. Beyond that, further acquisitions of Specialty Pharma products are still on the agenda.
